Next Phase Newsletter

A venture capital firm based in China makes early-growth stage investments, preferably from angel/seed to B), but will consider series C. The firm typically invests USD 1-30 million per company. The firm prefers to invest in companies based in China, but is open to outstanding Chinese-led companies based in the US and Canada. The firm is actively seeking new investment opportunities.

In the life sciences, the firm currently considers therapeutics and diagnostics in bone/joint diseases, renal diseases, autoimmune disease, cancer, and fibrosis. The firm is especially interested in immunotherapy, gene editing, and stem cell therapy that have preclinical data. Clinical data is desired, but not required.

The firm typically seeks Chinese-led teams with strong technical expertise and industry experience. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC based in Western Europe is currently raising a new fund which will be focused specifically on therapeutics. Around 50% of their new fund will be dedicated to venture building, and the other half will be dedicated to traditional venture investing. The firm will invest in European and Israeli companies, and will invest from lead identification to IND-stage, although the firm is open to investing in clinical-stage companies. The firm will invest between $5-25M per investment (seed, series A, series B).

The firm is looking to invest only in therapeutics. Within therapeutics, the firm is agnostic to modality. The firm is primarily interested in the indications of oncology (particularly glioblastoma, pancreatic cancer and sarcoma), rare diseases and CNS disorders, particularly those with a genetic origin. The firm is interested in First-In-Class and Best-In-Class therapeutics, but may consider repurposed therapeutics for CNS only.

The firm is interested in investing in experienced management teams. The firm prefers to co-invest, and may take a board seat, but does not require it.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Asia with additional offices in the USA makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based family office has started to make direct investments in companies in the life sciences space and looks to potentially make additional investments. Currently, the firm is most interested in medical device or diagnostics companies.

The firm is most interested in medical devices and diagnostics. The firm is opportunistic and will consider all types of technologies and indications.

The firm has no specific company requirements and prefers to invest alongside syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in California that was founded in 2016 is investing out of a $261M fund. The firm invests in many sectors, including cloud-based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical devices, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical devices, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A seed fund, based in Palo Alto focuses on applied AI technologies and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital firm founded in 2005 is headquartered in Singapore and Shanghai, with additional offices in Hong Kong, New York, and San Diego. In 2017, the firm closed its fifth fund, Fund V, of over $220M and is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in China and Southeast Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.